.An experiment applied a second-generation novel GLP-1/GIP dual receptor agonist, DA3-CH, to an MPTP-induced Parkinson’s mouse model and compared its neuroprotective effects with the GLP-1 single receptor agonist, liraglutide. Here, GCG is linked to Parkinson disease.